1.Primary renal aspergillosis and renal stones in both kidneys associated with hematopoietic stem cell transplant.
Hyunsung PARK ; Mi Jung LEE ; Yundeok KIM ; Yoo Hong MIN ; Soo Jeong KIM ; Dokyung KIM
Korean Journal of Hematology 2010;45(4):275-278
Invasive aspergillosis (IA) is a leading cause of infectious mortality in patients who have undergone a hematopoietic stem cell transplant (HSCT); the mortality due to IA ranges from 70% to 93% in HSCT patients. Early diagnosis and treatment are the cornerstones for the good prognosis of IA. Primary renal aspergillosis is an extremely rare presentation in patients who have undergone HSCT, and the risk factor for this uncommon presentation is not well known. We report a patient who developed primary renal aspergillosis and renal stones in both the kidneys after HSCT. Invasive renal aspergillosis was diagnosed after a nephrectomy, which was performed to treat massive renal hematoma.
Aspergillosis
;
Early Diagnosis
;
Hematoma
;
Hematopoietic Stem Cells
;
Humans
;
Kidney
;
Nephrectomy
;
Prognosis
;
Risk Factors
;
Transplants
2.MicroRNA-374a Expression as a Prognostic Biomarker in Lung Adenocarcinoma
Yeseul KIM ; Jongmin SIM ; Hyunsung KIM ; Seong Sik BANG ; Seungyun JEE ; Sungeon PARK ; Kiseok JANG
Journal of Pathology and Translational Medicine 2019;53(6):354-360
BACKGROUND: Lung cancer is the most common cause of cancer-related death, and adenocarcinoma is the most common histologic subtype. MicroRNA is a small non-coding RNA that inhibits multiple target gene expression at the post-transcriptional level and is commonly dysregulated in malignant tumors. The purpose of this study was to analyze the expression of microRNA-374a (miR-374a) in lung adenocarcinoma and correlate its expression with various clinicopathological characteristics.METHODS: The expression level of miR-374a was measured in 111 formalin-fixed paraffin-embedded lung adenocarcinoma tissues using reverse transcription-quantitative polymerase chain reaction assays. The correlation between miR-374a expression and clinicopathological parameters, including clinical outcome, was further analyzed.RESULTS: High miR-374 expression was correlated with advanced pT category (chi-square test, p=.004) and pleural invasion (chi-square test, p=.034). Survival analysis revealed that patients with high miR-374a expression had significantly shorter disease-free survival relative to those with low miR-374a expression (log-rank test, p=.032).CONCLUSIONS: miR-374a expression may serve as a potential prognostic biomarker for predicting recurrence in early stage lung adenocarcinoma after curative surgery.
Adenocarcinoma
;
Disease-Free Survival
;
Gene Expression
;
Humans
;
Lung Neoplasms
;
Lung
;
MicroRNAs
;
Polymerase Chain Reaction
;
Recurrence
;
RNA, Small Untranslated
3.ANNO: A General Annotation Tool for Bilingual Clinical Note Information Extraction
Kye Hwa LEE ; Hyunsung LEE ; Jin-Hyeok PARK ; Yi-Jun KIM ; Youngho LEE
Healthcare Informatics Research 2022;28(1):89-94
Objectives:
This study was conducted to develop a generalizable annotation tool for bilingual complex clinical text annotation, which led to the design and development of a clinical text annotation tool, ANNO.
Methods:
We designed ANNO to enable human annotators to support the annotation of information in clinical documents efficiently and accurately. First, annotations for different classes (word or phrase types) can be tagged according to the type of word using the dictionary function. In addition, it is possible to evaluate and reconcile differences by comparing annotation results between human annotators. Moreover, if the regular expression set for each class is updated during annotation, it is automatically reflected in the new document. The regular expression set created by human annotators is designed such that a word tagged once is automatically labeled in new documents.
Results:
Because ANNO is a Docker-based web application, users can use it freely without being subjected to dependency issues. Human annotators can share their annotation markups as regular expression sets with a dictionary structure, and they can cross-check their annotated corpora with each other. The dictionary-based regular expression sharing function, cross-check function for each annotator, and standardized input (Microsoft Excel) and output (extensible markup language [XML]) formats are the main features of ANNO.
Conclusions
With the growing need for massively annotated clinical data to support the development of machine learning models, we expect ANNO to be helpful to many researchers.
4.Retention Esophagitis as a Significant Clinical Predictor of Progression to Esophageal Cancer in Achalasia.
Haewon KIM ; Hyojin PARK ; HeeSeung CHOI ; Yooju SHIN ; Hyunsung PARK ; Young Hoon YOUN ; Jie Hyun KIM
Clinical Endoscopy 2018;51(2):161-166
BACKGROUND/AIMS: Chronic liquid and/or food stasis caused by retention esophagitis (RE) in achalasia is a notable endoscopic finding because of the presence of a thickened or whitish esophageal mucosa and histologically altered squamous hyperplasia. We aimed to identify the clinical features of RE associated with achalasia and to clarify the clinical definition of RE in achalasia as a precancerous lesion identified by analyzing biomarker expressions. METHODS: From 2006 to 2015, we retrospectively reviewed 37 patients with achalasia without previous treatment. Among them, 21 patients had diagnostic findings of RE (RE+) and 16 patients had no diagnostic findings of RE (RE−). Immunohistochemical staining of p53, p16, and Ki-67 was performed on the endoscopic biopsy tissues from the patients with achalasia and 10 control patients with non-obstructive dysphagia. RESULTS: The symptom duration and transit delay were significantly longer in the RE+ group than in the RE− group. We found particularly high p53 positivity rates in the RE+ group (p<0.001). The rate of p16 expression was also significantly higher in the RE+ group than in the other two groups (p=0.003). CONCLUSIONS: A high p53 expression rate was more frequently found in the RE+ group than in the other two groups. RE could be a meaningful clinical feature of achalasia for predicting esophageal carcinogenesis.
Biopsy
;
Carcinogenesis
;
Deglutition Disorders
;
Esophageal Achalasia*
;
Esophageal Neoplasms*
;
Esophagitis*
;
Humans
;
Hyperplasia
;
Mucous Membrane
;
Retrospective Studies
;
Tumor Suppressor Protein p53
5.Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Hyunsung PARK ; Haerim CHUNG ; Jungyeon LEE ; Jieun JANG ; Yundeok KIM ; Soo Jeong KIM ; Jin Seok KIM ; Yoo Hong MIN ; June Won CHEONG
Yonsei Medical Journal 2017;58(1):35-42
PURPOSE: Decitabine, a DNA hypomethylating agent, was recently approved for use in Korea for older adults with acute myeloid leukemia (AML) who are not candidates for standard chemotherapy. This study aimed to evaluate the role of decitabine as a first-line treatment for older adults with AML. MATERIALS AND METHODS: Twenty-four patients with AML who received at least one course of decitabine (20 mg/m²/d intravenously for 5 days every 4 weeks) as a first-line therapy at Severance Hospital were evaluated retrospectively. RESULTS: The median age of the patients was 73.5 years. The longest follow-up duration was 502 days. A total of 113 cycles of treatment were given to 24 patients, and the median number of cycles was four (range, 1–14). Thirteen patients dropped out because of death, no or loss of response, patient refusal, or transfer to another hospital. Twenty-one (87.5%) and 12 (50%) patients completed the second and fourth cycles, respectively, and responses to treatment were evaluated in 17. A complete response (CR) or CR with incomplete blood-count recovery was achieved in six (35.3%) patients, and the estimated median overall survival was 502 days. Ten patients developed grade >2 hematologic or non-hematologic toxicities. In univariate analysis, bone marrow blasts, lactate dehydrogenase, serum ferritin level, and bone marrow iron were significantly associated with response to decitabine. CONCLUSION: Five-day decitabine treatment showed acceptable efficacy in older patients with AML who are unfit for conventional chemotherapy, with a CR rate 35.3% and about a median overall survival of 18 months.
Aged
;
Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use
;
Azacitidine/*analogs & derivatives/therapeutic use
;
DNA Methylation
;
Female
;
Humans
;
Leukemia, Myeloid, Acute/*drug therapy/mortality
;
Male
;
Middle Aged
;
Remission Induction
;
Republic of Korea
;
Retrospective Studies
;
Treatment Outcome
6.Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee OH ; Dae Won JUN ; Hye Young KIM ; Seung Min LEE ; Eileen L. YOON ; Jungwook HWANG ; Jung Hwan PARK ; Hanbi LEE ; Wankyu KIM ; Hyunsung KIM
Clinical and Molecular Hepatology 2022;28(3):497-509
Background/Aims:
We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD).
Methods:
An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy.
Results:
DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels.
Conclusions
The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
7.HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma.
Hyunsung PARK ; Do Young KIM ; Soo Jeong KIM ; Haerim CHUNG ; Hyunsoo CHO ; Ji Eun JANG ; June Won CHEONG ; Yoo Hong MIN ; Jae Woo SONG ; Jin Seok KIM
Cancer Research and Treatment 2018;50(4):1121-1129
PURPOSE: Although hepatitis B surface antigen (HBsAg)–negative, hepatitis B core antibody (anti-HBc)–negative patients are not considered to be at risk for hepatitis B virus (HBV)–related hepatitis, the actual risk remains to be elucidated. This study aimed to evaluate the risk of HBV-related hepatitis in HBsAg-negative, anti-HBc–negative patients receiving autologous stem cell transplantation (ASCT) for multiple myeloma (MM) or malignant lymphoma. MATERIALS AND METHODS: We retrospectively reviewed data from 271 HBsAg-negative patients (161 anti-HBc–negative and 110 anti-HBc–positive at the time of ASCT) who received ASCT for MM or lymphoma. The risk of HBV-related hepatitis was analyzed according to the presence of anti-HBc. HBV serology results at the time of ASCT were compared with those at the time of diagnosis of MM or lymphoma. RESULTS: Three patients (two anti-HBc–negative MMs and one anti-HBc–positive MM) developed HBV-related hepatitis after ASCT. The rate of HBV-related hepatitis did not differ among patients with or without anti-HBc status (p=0.843). HBV-related hepatitis more frequently occurred in MM patients than in lymphoma patients (p=0.041). Overall, 9.1% of patients (16.7% with MM and 5.4% with lymphoma) who were HBsAg–negative and anti-HBc–positive at the time of diagnosis had lost anti-HBc positivity during chemotherapy prior to ASCT. CONCLUSION: Our data suggest that HBsAg-negative, anti-HBc–negative patients at the time of ASCT for MM or lymphoma still might be at a risk for HBV-related hepatitis.
Diagnosis
;
Drug Therapy
;
Hepatitis B Surface Antigens
;
Hepatitis B virus
;
Hepatitis B*
;
Hepatitis*
;
Humans
;
Lymphoma*
;
Multiple Myeloma*
;
Retrospective Studies
;
Stem Cell Transplantation*
;
Stem Cells*